Bharat Biotech, which developed the drug that has shown an efficacy of 81% in the initial phase 3 trial analysis, would submit the clinical trial data to the government in the coming days for review, said a senior official at CDSCO, which is under the Drugs Controller General of India (DCGA).
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.